Dainippon Sumitomo Pharma Expands its Oncology Presence with Boston Biomedical Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 3 (Table of Contents)
Published: 9 Mar-2012
DOI: 10.3833/pdr.v2012.i3.1695 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
After gaining an option in 2011 to license Japanese rights to Boston Biomedical’s BBI608, an orally administered cancer stem cell (CSC) inhibitor, Japan’s Dainippon Sumitomo Pharma (DSP) has agreed to acquire the US biotech for as much as US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS